RZLT: Rezolute, Inc. Company Short-Term Debt

Symbol and logo of brand Rezolute, Inc. (RZLT)

Rezolute, Inc. (RZLT) operations are characterized by minimal environmental impact and strict adherence to disposal regulations. The business relies on creating unique therapeutic solutions for rare pathologies, ensuring global reach and high profitability. The price action of the securities on GURU.Markets recorded a value of 0.00. However, risk remains significant due to a lack of sales and dependence on the outcome of drug trials for hyperinsulinemia.

RZLT (Rezolute Inc) Company Short-Term Debts history from 07/04/2022 to 10/30/2026

RZLT (Rezolute Bio): analytical breakdowns and indicator data

- current quotes and average value forecast:
Price Chart Rezolute|RZLT - Fair Value Consensus
- market capitalization information:
Market Value Rezolute, Inc.|RZLT - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share Rezolute|RZLT - Book Capitalization|Market Cap to Net Assets Ratio rezolutebio.com|RZLT - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Rezolute, Inc.|RZLT - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Rezolute, Inc.|RZLT - Company Cumulative Debt|Debt to Book Value Rezolute, Inc.|RZLT - Amount of Long-Term Liabilities|Company Short-Term Debts Rezolute|Quick Ratio rezolutebio.com
- net income and valuation multiples indicators:
RZLT - Company Net Income
Basic company analysis:Rezolute - RZLT
Mass-produced product of Rezolute Bio

Rezolute, Inc. (RZLT) develops unique therapies for rare metabolic pathologies, maintaining a monopoly status in the treatment of hyperinsulinism. This indicator aggregates all obligations with a maturity of up to one year, measuring the current accounts payable burden. Analyzing this metric allows for an assessment of the issuer's ability to service debt without compromising liquidity. Rising borrowings signal refinancing risks amid market turbulence. The trajectory of short-term debt clearly captures the dynamics of the business's financial stability.

Who Rezolute, Inc. competes with

ASND - Company Short-Term Debt|Company Short-Term Loans and Borrowings MDGL (Madrigal Pharmaceuticals Inc)|Corcept (CORT) - Company Short-Term Debt|Company Current Liabilities Rhythm Corp|AKRO (Akero Therapeutics) - Company Short-Term Debts|Company Short-Term Debts metsera.com|Company Current Liabilities MLTX (MoonLake)|CRNX (Crinetics Pharmaceuticals, Inc.) - Company Short-Term Loans and Borrowings|Company Short-Term Debt NewAmsterdam Pharma N.V. NAMS|SLNO - Company Current Liabilities|Amicus Therapeutics - Company Short-Term Debts|Short-Term Debt 89bio.com|AGIO (Agios Pharmaceuticals, Inc.) - Company Current Liabilities|GPCR: Amount of Current Liabilities|MDXG (MiMedx Group) - Company Short-Term Debts|Company Short-Term Debts Lexicon Corp|Company Short-Term Debts MBX|Company Short-Term Debt ALT (altimmune.com)|Company Short-Term Debt Aardvark Therapeutics AARD|Sagimet Biosciences, Inc. (SGMT) - Short-Term Debt|BIOA - Company Short-Term Debt|BMEA: Company Short-Term Debt|QNCX: Company Short-Term Debts|GUTS - Short-Term Debt Volume|Company Short-Term Debt vTv Therapeutics, Inc.|Agape ATP Corp. (ATPC) - Short-Term Debt Volume|Company Short-Term Debt Pluri Inc. (PLUR)|Company Current Liabilities synlogictx.com SYBX|Company Short-Term Debt Lipocine Inc. LPCN|Company Short-Term Loans and Borrowings MTNB|Spruce Biosciences - Company Short-Term Debts|Short-Term Debt Galecto Inc|CTCX (Carmell Corp) - Company Current Liabilities|Current Liabilities LUMO (Lumos Therapeutics)|Company Short-Term Debt Organovo Holdings, Inc.|Short-Term Debt radiuspharm.com RDUS